Navigation Links
New strategies against bird flu
Date:6/26/2008

The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). This fatal condition is a massive reaction of the body during which the lung becomes severely damaged. ARDS can be induced by various bacterial and viral infections, but also by chemical agents. These could be toxic gases that are inhaled or gastric acid when aspirated. Once ARDS has developed, survival rates drop dramatically. Among patients infected with H5N1 bird flu, about 50 percent die of ARDS.

An international team of scientists has been addressing the underlying disease mechanisms for the past five years. The team involved researchers from leading institutions in Vienna, Stockholm, Cologne, Beijing, Hongkong, and Toronto as well as the US-army at Fort Detrick. The international effort was coordinated by Josef Penninger and Yumiko Imai of the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences.

A first breakthrough came in 2005 when IMBA-scientists identified ACE2 as the essential receptor for SARS virus infections and showed that ACE2 can protect from acute lung failure in disease models (Imai et al. Nature 2005; Kuba et al. Nature Medicine 2005). Based on these data, ACE2 is now under therapeutic development.

In a paper published by Cell this week, the authors describe an essential key injury pathway that is operational in multiple lung injuries and directly links oxidative stress to innate immunity. They also report for the first time a common molecular disease pathway explaining how diverse non-infectious and infectious agents such as anthrax, lung plague, SARS, and H5N1 avian influenza may cause severe and often lethal lung failure with similar pathologies.

To identify these pathways, the researchers studied numerous tissue samples from deceased humans and animals. Victims of bird flu and SARS were examined in Hongkong, and the US-army provided samples from animals infected with Anthrax and lung plague. Common to all ARDS samples was the massive amount of oxidation products found within the cells. Based on these findings, the scientists showed that oxidative stress is the common trigger that ultimately leads to lung failure.

To elucidate the entire pathway, Yumiko Imai of IMBA developed several mouse models. She was now able to show that a molecule called TLR4 (Toll-like receptor 4) is responsible for initiating the critical signalling pathway. TLR4 is displayed at the surface of certain lung cells called macrophages, important players of the bodys immune system. Once activated, TLR4 initiates an entire chain reaction which ends with the fatal failure of the lungs. Surprisingly, mice challenged with inactivated H5N1 avian influenza virus also dveloped the full reaction. On the other hand, mutant mice in which the function of TLR4 was genetically impaired were protected from lung failure in repsonse to the inactivated virus.

Based on these findings, the researchers can now outline a common molecular disease pathway: Microbial or chemical lung pathogens trigger the oxidative stress machinery. Oxidation products are intrepreted as danger-signals by the receptor TLR4. Subsequently, the bodys innate immune system is activated. This defense machinery in turn leads to a chain of reactions with severe and often fatal lung damage as a consequence.

For Yumiko Imai, a Postdoc in Josef Penningers team and pediatrician by training, these results are highly satisfying. Her motivation to study ARDS is based on personal experience in over 10 years at a pediatric intensive care unit. I have seen so many children die from acute lung failure and felt utterly helpless, Imai says. Since we found a common injury pathway, our hopes are high that we may be able to develop a new and innovative strategy for tackling severe lung infections.


'/>"/>

Contact: Dr. Heidemarie Hurtl
hurtl@imp.ac.at
43-179-730-3625
Research Institute of Molecular Pathology
Source:Eurekalert

Related biology technology :

1. Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference
2. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
3. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
4. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
5. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
6. Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance
7. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
8. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
9. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
10. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
11. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017   Micralyne Inc., ... and a primary supplier of sensors, is pleased ... Placentia, California to develop and ... (TSV).  The joint development of this technology leverages ... a truly flexible and cost effective Metal TSV ...
(Date:6/14/2017)... ... June 13, 2017 , ... ... the phenotype of an organism on a molecular level that is closely ... processing remain major bottlenecks to biomarker discovery in clinical-based metabolomics research. , ...
(Date:6/13/2017)... ... June 13, 2017 , ... Three ... Phase 1 Ventures (P1V) program. PolyCeramX, Recensa Therapeutics and Regennera, all P1V participants, ... , Phase 1 Ventures is a startup accelerator that helps launch and ...
(Date:6/13/2017)... PA and London UK (PRWEB) , ... June 13, 2017 , ... ... for Information and Study on Clinical Trial Participation (CISCRP) and the Society for Clinical ... Expert speakers will provide background on the purpose of eConsent and the ability for ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOGĀ“s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):